Log In
Print
BCIQ
Print
Print this Print this
 

Actimab-A

  Manage Alerts
Collapse Summary General Information
Company Actinium Pharmaceuticals Inc.
DescriptionActinium-225 attached to the anti-CD33 mAb lintuzumab (HuM195)
Molecular Target CD33
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today